Document is current

Article History

Received: 25 February 2026

Accepted: 6 April 2026

First Online: 22 May 2026

Declarations

:

: Niloufar Ebrahimi reports having received grant support from GlomCon in the past. Ali Poyan Mehr reports receiving research grants from Travere Therapeutics and Roche; consulting fees from Novartis and Metyos; and serving in leadership roles as Founder and President of the GlomCon Foundation and as a board member of the Kidney Health Initiative. Haresh Selvaskandan reports consulting work with Alexion and George Clinical; receipt of research funding from Omeros; honoraria from Vifor CSL; and travel grants from Stanningley Pharma and Pharmacosmos. Harish Seetapathy has served on advisory boards for Vera Therapeutics and Travere Pharmaceuticals. Zainab Obaidi serves as a paid consultant for Sparsentan (Travere Therapeutics), Vera Therapeutics, Amgen, and TARPEYO (Calliditas). Zainab Obaidi also participated in advisory boards for Sparsentan (Travere Therapeutics) in 2023, TARPEYO (Calliditas) in 2024, Atacicept (Vera Therapeutics) in 2024, and Avacopan (Amgen) in 2024. Swati Arora serves on the speaker bureau and advisory board for Calliditas, Aurinia, and Travere, and on the speaker bureau for GSK, Boehringer Ingelheim, Novartis, Otsuka, and Amgen. Arun Rajasekaran has received research support from Otsuka and serves as a consultant for Vertex Pharmaceuticals, Vera Therapeutics, and Travere Therapeutics. Arun Rajasekaran serves on the advisory board for Vera Therapeutics, Vertex Pharmaceuticals, Otsuka, Travere Therapeutics, Novartis Pharmaceuticals, and Calliditas Therapeutics. Tripti Singh serves on the advisory board for Novartis and participates in PEER teaching seminars for Travere Therapeutics. Edgar Lerma has served on the Speakers Bureau, Advisory Board, and Steering Committee for Opko, Otsuka, Vera Therapeutics, Vertex Pharmaceuticals, and Travere. Sayna Norouzi reports receiving consulting fees and honoraria from Calliditas, Otsuka, Alexion, Travere, Novartis, Sanofi, Amgen, and Vera Therapeutics; serves as a member of the Board of Directors for the IgAN Foundation; and has received grant support from GlomCon, the IgAN Foundation, the American Society of Nephrology (ASN), and Otsuka. Zainab Obaidi serves as a paid consultant for Sparsentan (Travere Therapeutics), Vera Therapeutics, Amgen, and TARPEYO (Calliditas). Zainab Obaidi also participated in advisory boards for Sparsentan (Travere Therapeutics) in 2023, TARPEYO (Calliditas) in 2024, Atacicept (Vera Therapeutics) in 2024, and Avacopan (Amgen) in 2024. Swati Arora serves on the speaker bureau and advisory board for Calliditas, Aurinia, and Travere, and on the speaker bureau for GSK, Boehringer Ingelheim, Novartis, Otsuka, and Amgen. Arun Rajasekaran has received research support from Otsuka and serves as a consultant for Vertex Pharmaceuticals, Vera Therapeutics, and Travere Therapeutics. Arun Rajasekaran serves on the advisory board for Vera Therapeutics, Vertex Pharmaceuticals, Otsuka, Travere Therapeutics, Novartis Pharmaceuticals, and Calliditas Therapeutics.Tripti Singh serves on the advisory board for Novartis and participates in PEER teaching seminars for Travere Therapeutics.Edgar Lerma has served on the Speakers Bureau, Advisory Board, and Steering Committee for Opko, Otsuka, Vera Therapeutics, Vertex Pharmaceuticals, and Travere. Sayna Norouzi reports receiving consulting fees and honoraria from Calliditas, Otsuka, Alexion, Travere, Novartis, Sanofi, Amgen, and Vera Therapeutics; serves as a member of the Board of Directors for the IgAN Foundation; and has received grant support from GlomCon, the IgAN Foundation, the American Society of Nephrology (ASN), and Otsuka.